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Abstract: Background: Since limited data are available about the prevalence of Merkel cell 
polyomavirus (MCPyV) and the genetic variability of its noncoding control region (NCCR) in the 
context of immunosuppression, this study aimed to investigate the distribution of MCPyV in 
anatomical sites other than the skin and the behavior of NCCR among an HIV-1-positive 
population. Methods: Urine, plasma, and rectal swabs specimens from a cohort of 66 HIV-1-
positive patients were collected and subjected to quantitative real-time polymerase chain reaction 
(qPCR) for MCPyV DNA detection. MCPyV-positive samples were amplified by nested PCR 
targeting the NCCR, and NCCRs alignment was carried out to evaluate the occurrence of 
mutations and to identify putative binding sites for cellular factors. Results: MCPyV DNA was 
detected in 10/66 urine, in 7/66 plasma, and in 23/66 rectal samples, with a median value of 5 × 102 
copies/mL, 1.5 × 102 copies/mL, and 2.3 × 103 copies/mL, respectively. NCCR sequence analysis 
revealed a high degree of homology with the MCC350 reference strain in urine, whereas 
transitions, transversions, and single or double deletions were observed in plasma and rectal 
swabs. In these latter samples, representative GTT and GTTGA insertions were also observed. 
Search for putative binding sites of cellular transcription factors showed that in several strains, 
deletions, insertions, or single base substitutions altered the NCCR canonical configuration. 
Conclusions: Sequencing analysis revealed the presence of numerous mutations in the NCCR, 
including insertions and deletions. Whether these mutations may have an impact on the 
pathogenic features of the virus remains to be determined. qPCR measured on average a low viral 
load in the specimens analyzed, with the exception of those with the GTTGA insertion. 
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1. Introduction  
Human polyomaviruses (HPyVs) include ubiquitous, clinically silent viral pathogens that 
establish a symbiotic relationship with their human hosts [1]. Merkel cell polyomavirus (MCPyV) 
is a small, nonenveloped, double-stranded DNA virus, identified in 2008 [2] and related to the 
progenitors BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV). Most MCPyV infections are 
asymptomatic, and serological studies showed that 50%–80% of the healthy individuals present 
MCPyV-specific antibody responses [3,4]. After primary infection, HPyVs establish a lifelong 
persistence in different anatomical sites, such as lymphoid tissue (JCPyV), renal epithelium (JCPyV 
and BKPyV), and skin (MCPyV) [5]. Recently, a high prevalence of MCPyV has also been found in 
respiratory and stool samples from immunocompromised patients, adding important information 
on MCPyV prevalence and persistence in the respiratory and gastrointestinal tract [4–8]. MCPyV 
shares the genomic structure of BKPyV and JCPyV, with a circular genome divided into three 
functional regions: early, late, and interposed between these regions, the noncoding control region 
(NCCR). The early region encodes the large T antigen (LT), small T antigen (sT), 57 kT antigen (57 
kT), and ALTO (alternate frame of the large T open reading frame). The late region is transcribed 
in the opposite direction and encodes the structural components of the virus capsid: virus protein 
1 (VP1) and the minor capsid proteins virus protein 2 (VP2). MCPyV does not seem to express virus 
protein 3 (VP3), and virions do not seem to contain VP3, despite an in-frame internal adenin-timin-
guanine (ATG) start codon in the VP2 gene [9]. The NCCR contains the origin of replication and 
bidirectional promoter elements [4,10,11]. The two main spliced products, LT and sT antigens, are 
involved in the viral infectious cycle, in cell cycle progression, and in malignant transformation of 
the host cell [12]. The continued expression of the MCPyV viral oncogenes sT and LT with a C-
terminal truncation is required for Merkel cell carcinoma (MCC) development [13]. Although these 
findings provide strong evidence that MCPyV is a major causative agent of this skin cancer, 
whether the NCCR can influence the outcome of the infection remains elusive. It is well 
documented that one of the remarkable features of NCCRs is the occurrence of rearrangements, 
which allow to classify BKPyV and JCPyV in archetype (ww) and rearranged (rr) [14–17]. The 
archetype form is predominant in the urine of healthy individuals and represents the transmissible 
form of the virus circulating in the human population and the persistent form in the host. The rr-
sequences, characterized by deletions and/or duplications compared with the archetype, are 
thought to derive from the archetype form during or after reactivation from persistence in vivo, 
often associated with disease [16,17]. Mutations and rr-forms also emerge in permissive cells in 
vitro [14,18–21], when replication occurs without the constraints of an effective host cellular 
immune response. The study of the NCCR during host immunosuppression, a critical cofactor for 
BKPyV, JCPyV, and MCPyV pathogenesis, is important because of the association of the rr-variants 
with specific human diseases such as polyomavirus nephropathy (PVAN) associated to BKPyV 
reactivation or progressive multifocal leukoencephalopathy (PML) caused by JCPyV [22–24]. 
Limited data are currently available about the possible relationship between MCPyV NCCRs 
mutations/rearrangements and the development of MCPyV-related disease. Hashida and 
coworkers evaluated the genetic variability of MCPyV NCCR in skin swab specimens of healthy 
individuals with distinct ethnicities and geographic origins, showing that insertions and deletions 
could be used to classify NCCR into five genotypes. Based on this classification, a tandem repeat 
was found exclusively in the NCCR of Japanese patients with MCC, while white patients from 
Europe or North America presented other genotypes [13]. Delbue and colleagues performed the 
MCPyV NCCR molecular characterization on cerebrospinal fluid (CSF) samples collected from 
patients affected by neurological disorders. The results obtained showed the presence of MCPyV 
NCCR IIc strain, according to Hashida’s NCCR classification [10]. Thus, given this background, the 
objective of the present study was to investigate the following: first, the prevalence of MCPyV in 
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urine, plasma, and rectal swabs specimens among a HIV-1-positive population; and second, since 
little is known about NCCR alterations in MCPyV strains circulating in this population, the features 
of the MCPyV NCCR, focusing on NCCR variability. A search for putative binding sites of cellular 
transcription factors was also performed in order to verify whether mutations and/or 
rearrangements detected within the NCCR could fall in these binding sites. The assessment of 
NCCR region in different anatomical sites could help in advancing the understanding of MCPyV 
biology and the role of NCCR variability in the context of immunosuppression. 
2. Materials and Methods 
2.1. Study Population 
A cross-sectional study including a cohort of 66 HIV-1-positive patients, admitted to the 
Infectious Diseases Clinic of the Polyclinic Tor Vergata Foundation from January 2019 to December 
2019, was performed. Among the enrolled patients, 22 were new diagnoses naive to treatment and 
44 were experienced patients on treatment with a triple-based antiretroviral regimen including 
protease/reverse transcriptase/integrase inhibitors. From this cohort (55 males/11 females, age 
ranged from 21 to 76 years old: mean age ± standard deviation: 40.5 years old; median: 39.9 years 
old), a sample of urine, plasma, and rectal swab were collected. In detail, 66 plasma, 66 urine, and 
66 rectal swabs were obtained for a total of 198 specimens. Demographic and clinical characteristics 
are presented in Table 1. The study was approved by the local Ethic Committee of the University 
Hospital Tor Vergata (Rome, Italy) (protocol number 0027234/2018, 19 December 2018), and 
informed consent was obtained from patients. 









Range: 21–68 years old 
Mean: 39.27 years old 
1.26 × 103–10 × 106 
copies/mL 
9–890/mm3 
Experienced  44 
Male: 39; 
Female: 5 
Range: 21–76 years old 
Mean: 43.7 years old 
TND-27 × 105 copies/ml 312–1178/mm3 
n: number; TND: Target not detected. 
2.2. MCPyV DNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (qPCR)  
Total DNA was extracted from urine and plasma by DNeasy®  Blood & Tissue Kit (QIAGEN, 
S.p.A, Milan, Italy) and from rectal swab, using the Stool DNA Isolation Kit (NORGEN BIOTEK, 
Thorold, ON, Canada) according to the manufacturer’s instructions. The extracted nucleic acids 
were eluted in a final volume of 100 μL, and DNA was evaluated for its PCR suitability by 
amplifying the β-globin gene sequences [25]. Specific quantitative qPCR assays were performed 
using TaqMan-based qPCR, employing primers and probes for MCPyV sT, as previously described 
[26,27]. All samples were tested in triplicate, and the number of viral copies was calculated from 
standard curves constructed using a ten-fold dilution series of plasmids pMCV-R17a containing 
the entire genome of MCPyV (Addgene, #24729) (dilution range: 108–10 copies/mL). The lower 
detection limit of the assay was 10 DNA copies of the target gene per amplification reaction, 
corresponding to 10 copies per reaction (10 copies/reaction). The results were reported as copies/mL. 
2.3. MCPyV Nested PCR  
MCPyV-positive DNA samples were subjected to nested PCR for the amplification of NCCR 
region. Two sets of primers, ORIF1/ORIR1 (nucleotide positions 4832–4853 and nucleotide 
positions 5334–5314) and ORIF2/ORIR2 (nucleotide positions 5077–5100 and nucleotide positions 
5280–5261), were employed to generate an NCCR fragment of 504 and 203 base pair (bp). 
Numbering of nucleotides was based on the sequence of MCC350, a strain of North American 
origin (GenBank: EU375803) [2]. In detail, PCR reactions were carried out following a published 
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protocol [13]. PCR products were analyzed on 2% agarose gels by ethidium bromide staining. The 
positive PCR products were purified using the MinElute PCR Purification Kit (QIAGEN, Italy) and 
confirmed by sequencing, using sense and antisense primers, by a dedicated facility (Bio-Fab 
research s.r.l., Rome, Italy). Sequences were generated using the Big Dye Terminator Sequencing 
method (Life Technologies) on the ABI 3730 sequencer (Life Technologies, Monza, Italy), and 
analyzed with the Sequencing Analysis 5.2 software (Life Technologies). 
2.4. NCCR Alignment and Analysis of Putative Binding Sites 
The obtained sequences were compared to the reference strain (EU375803). Sequence 
alignment was performed using ClustalW2 [28] available on the European Molecular Biology 
Laboratory–European Bioinformatics Institute (EMBL-EBI) website using default parameters. The 
identification of putative binding sites for several transcription factors was carried out using 
TFBIND, available at http://tfbind.hgc.jp/ [29]. 
2.5. Statistical Analysis 
MCPyV detection was summarized by counts and proportions. If continuous variables were 
normally distributed, they were expressed as mean ± SD; if not, they were expressed by median 
and range. The χ2 test was performed to evaluate differences for categorical variables. Group 
differences for continuous variables were tested using Student’s t-test or Mann–Whitney U-test, for 
normally and non-normally distributed variables, respectively. Associations between two 
continuous variables were examined by Pearson or Spearman correlation for normal or non-normal 
variables. Differences in viral loads, among the three anatomical sites, were analyzed using 
Kruskal–Wallis test. A p-value less than 0.05 was considered statistically significant. 
3. Results 
3.1. MCPyV DNA Detection and Quantification by Real-Time qPCR Analysis 
Each DNA sample (66 urine, 66 plasma, and 66 rectal swabs for a total of 198 specimens) was 
tested for the presence of MCPyV. Overall, MCPyV DNA was detected in 10/66 (15%) urine, in 7/66 
(11%) plasma, and in 23/66 (35%) rectal samples. Specifically, among the enrolled population (22 
naive and 44 experienced patients), MCPyV was detected in 12 out of 22 naive and in 19 out of 44 
experienced patients. In naive patients, MCPyV DNA was detected in 5/12 urine, 4/12 plasma, and 
in 9/12 rectal swabs. Instead, in experienced patients, MCPyV was detected in 5/19 urine, 3/19 
plasma, and 14/19 rectal samples, respectively (Table 2). Overall, MCPyV DNA was found in a 
higher percentage among naïve versus experienced patients, either in the specific compartment or 
in all compartments together (urine: naïve 22.73%, experienced 11.36%; plasma: naïve 18.18%, 
experienced 6.82%; rectal swabs: naïve 40.91%, experienced 31.82%; overall sites: naïve 54.55%, 
experienced 43.18%) (Table 2). Results of qPCR showed that the median cycle threshold value (Ct) 
was 34.36 in urine (interquartile range (IQR) 30.08–36.07), 34.92 in plasma (IQR 33.57–36.78), 
whereas, in rectal swabs, median Ct was 31.57 (IQR 30.34–34.92). Analysis of qPCR results showed 
low amounts of viral MCPyV DNA with a median value of 5.15 × 102 copies/mL (IQR 4.5 × 102–5.4 
× 102) in urine, 1.5 × 102 copies/mL (IQR 1.3 × 102–2.0 × 102) in plasma, and 2.3 × 103 copies/mL (IQR 
1.8 × 103–4.1 × 103) in rectal samples, with a statistical significant difference (p < 0.001). No significant 
association was found between the presence of MCPyV DNA and MC viral load versus age, gender, 
and HIV patient’s status (naïve/experienced) at enrollment time, although the mean age of patients 
with MCPyV DNA in plasma was lower than that found in patients without MCPyV DNA in 
plasma (p = 0.042). Finally, detection of MCPyV did not show a correlation with HIV-1 load at 
enrollment or CD4+ cell counts. 
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Table 2. Detection and quantification of Merkel cell polyomavirus (MCPyV) DNA by real-time 
qPCR. 
HIV-1 Status Patients, n. MCPyV+ Patients, n. MCPyV+ Samples 
Naive Naive Urine Plasma Rectal Swab 
22/66 12/22 5 4 9 
Experienced Experienced    
44/66 19/44 5 3 14 
HIV-1 Status 
MCPyV DNA Detection % 
Overall Sites Urine Plasma  Rectal Swab 
Naive 54.55 22.73 18.18 40.91 
Experienced 43.18 11.36 6.82 31.82 
  qPCR results (median value)  
 Urine Plasma Rectal Swab  
 5.15 × 10
2 copies/mL 
(IQR 4.5 × 102–5.4 × 102) 
1.5 × 102 copies/mL 
(IQR1.3 × 102–2.0 × 102) 
2.3 × 103 copies/mL  
(IQR1.8 × 103–4.1 × 103) 
 
n: number; MCPyV+: MCPyV DNA positive. 
3.2. Genetic Analysis of NCCR  
Analysis of MCPyV NCCR regions obtained from positive urine, plasma, and rectal swabs of 
HIV-1-positive subjects was carried out. The amplified NCCRs, spanning from nucleotide position 
5077 to 5280, were compared with the reference sequence of the prototype North American strain 
MCC350 [2] (Figure 1).  
 
Figure 1. Schematic representation of the MCPyV genome (strain MCC350). The double-stranded 
DNA genome is 5387 bp in length. The early region encodes the large T antigen (LT), small T antigen 
(sT), 57 kT antigen (57 kT) and ALTO (alternate frame of the large T open reading frame). These 
genes function to allow for viral DNA replication. The late region is transcribed in the opposite 
direction and encodes the structural components of the virus capsid: virus protein 1 (VP1) and the 
minor capsid proteins virus protein 2 (VP2). MCPyV does not seem to express virus protein 3 (VP3), 
and virions do not seem to contain VP3, despite an in-frame internal ATG start codon in the VP2 
gene. At the top of the figure, the amplified noncoding control region (NCCR) of 203 base pair (bp) 
(5077–5280 bp). Putative binding sites for cellular transcription factors are highlighted in different 
colors as follows: AP-1: 5104–5114 nucleotide position (5′-GATGATGCCCC-3′); 5164–5172 
nucleotide position (5′-CTTTGTAAG-3′); 5257–5265 nucleotide position (5′-GTTTATCAG-3′); 5261–
5269 nucleotide position (5′-ATCAGTCAA-3′); NF1: 5088–5105 nucleotide position (5′-
TATTGGCCAGCAGTGTG-3′); TST1: 5200–5214 nucleotide position (5′-
GTTGAAAAAAAGTTA-3′); OCT1: 5116–5129 nucleotide position (5′-CATCCTGAAAAATA-
3′); 5143–5146 nucleotide position (5′-ACTCTTTTAATG-3′); NFκB: 5188–5197 nucleotide 
position (5′-CGGGCCTCCC-3′); TATA-like sequences: 5146–5160 nucleotide position (5′-
CTTTTAATGTCCTCC-3′); 5202–5212 nucleotide position (5′-TGAAAAAAAG-3′); 5256–5265 
nucleotide position (5′-TGTTTATCAG-3′). 
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The area highlighted in light grey represents overlapping areas within one or more binding 
sites. Numbering of nucleotides was based on the sequence MCC350, a strain of North American 
origin (GenBank: EU375803) [2]. 
The genetic analysis of NCCRs obtained from 10 out of 66 (15%) positive urine (MCPyV 
11,27,30,40,65 belonging to experienced (E) patients and MCPyV 19,36,38,47,64 belonging to naive 
(N) patients) showed an NCCR characterized by a high degree of homology with the prototype 
strain, despite the presence of some deletions or mutations (Figure 2). Specifically, a 6 bp deletion 
(CCCCCC, positions 5111–16) in MCPyV 30, a 2 bp deletion (CC, positions 5111–12) in MCPyV 11 
and 19, and a 2 bp deletion (AA, positions 5126–27) in MCPyV 36 and 38 were observed (Figure 2). 
Transitions were found from nucleotide positions 5145 to 5160. In particular, 5148 T to C transition 
was detected in MCPyV 27, 30, 36, 47, 5220 T to C transition was observed in MCPyV 30 and 36, 
instead, the 5175 A to T and the 5176 A to T transversions were found in MCPyV 36 (Figure 2). 
MCPyV 36 presented also a 6 bp (TTTTGT) deletion between nucleotides 5254–5259 (Figure 2).  
 
Figure 2. Sequence analysis of the MCPyV NCCR recovered from urine. The alignment is shown 
between the nucleotide sequence from 5077 to 5280 of the published sequence of MCPyV in 
GenBank (NCBI) (EU375803) [2] and that obtained from the sequencing of urine positive for 
MCPyV NCCR (MCPyV 11,19,27,30,36,38,40,47,64,65). AP-1: 5104–5114 nucleotide position (5′-
GATGATGCCCC-3′); 5164–5172 nucleotide position (5′-CTTTGTAAG-3′); 5257–5265 nucleotide 
position (5′-GTTTATCAG-3′); 5261–5269 nucleotide position (5′-ATCAGTCAA-3′); NF1: 5088–
5105 nucleotide position (5′-TATTGGCCAGCAGTGTG-3′); TST1: 5200–5214 nucleotide 
position (5′-GTTGAAAAAAAGTTA-3′); OCT1: 5116–5129 nucleotide position (5′-
CATCCTGAAAAATA-3′); 5143–5146 nucleotide position (5′-ACTCTTTTAATG-3′); NFκB: 
5188–5197 nucleotide position (5′-CGGGCCTCCC-3′); TATA-like sequences: 5146–5160 
nucleotide position (5′-CTTTTAATGTCCTCC-3′); 5202–5212 nucleotide position (5′-
TGAAAAAAAG-3′); 5256–5265 nucleotide position (5′-TGTTTATCAG-3′); E: experienced HIV-1-
positive patients; N: naive HIV-1-positive patients. 
Nucleotide substitutions are in bold red text. Deletions are indicated by bold and red dashes. 
The highlighted in light gray represents overlapping areas within one or more binding sites. The 
number of base pair (bp) of each sequence is reported on the right of the Figure. 
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In the positive plasma samples (7/66, 11%) (MCPyV 26,35,42 belonging to experienced (E) 
patients and MCPyV 13,21,36,41 belonging to naïve (N) patients), several mutations/deletions were 
found (Figure 3). In detail, the 5101 T to G transversion, the 5102 G to T transversion, the 5109 T to 
C transition, the 5148 T to C transition, and the 5220 T to C transition were found in MCPyV 13 
(Figure 3). Additionally, a deletion of a 2 bp sequence (CC) at nucleotide positions 5111–5112 and 
a deletion of a 2 bp sequence (AA) at nucleotide positions 5126–5127 were found. Similarly, MCPyV 
21, 26 and 35 showed 2 bp deletions (CC) at nucleotide positions 5111–5112 and 5126–27 (AA). This 
latter deletion was also observed in strains 36 and 41 (Figure 3). Single point mutations were also 
observed in several strains: a 5104 G to T transversion and a 5105 A to T transversion in MCPyV 21, 
a 5108 A to T transversion in MCPyV 36 and 42, and a 5109 T to C transition in MCPyV 13. Moreover, 
MCPyV 36 and 42 presented a 5112 C to G transversion, whereas the 5148 T to C transition was 
found in MCPyV 13, 26, 36, and 41. A single 5134 A deletion was present in MCPyV 35 and 41 
(Figure 3). Additionally, the 5189 G deletion and the 5210 A deletion were detected in MCPyV 26 
and 35, and the 5207 A deletion was found in MCPyV 36 and 42. The 5190 G to C transversion was 
found in MCPyV 42, and the 5220 T to C transition was found, in parallel, in MCPyV 13, 36, and 42 
(Figure 3). Between positions 5253 and 5260, homology analysis and multiple alignments did not 
show differences compared with the prototype strain with the exception of MCPyV 36 that 
presented an 8 bp deletion (TTTTGTTT) (Figure 3). Interestingly, a GTTGA insertion into 
nucleotide positions 5210–5211 was observed in MCPyV 13 and 36.  
 
Figure 3. Sequence analysis of the MCPyV NCCR recovered from plasma. The alignment is shown 
between the nucleotide sequence from 5077 to 5280 of the published sequence of MCPyV in 
GenBank (NCBI) (EU375803) [2] and that obtained from the sequencing of plasma positive for 
MCPyV NCCR (MCPyV 13,21,26,35,36,41,42). AP-1: 5104–5114 nucleotide position (5′-
GATGATGCCCC-3′); 5164–5172 nucleotide position (5′-CTTTGTAAG-3′); 5257–5265 nucleotide 
position (5′-GTTTATCAG-3′); 5261–5269 nucleotide position (5′-ATCAGTCAA-3′); NF1: 5088–
5105 nucleotide position (5′-TATTGGCCAGCAGTGTG-3′); TST1: 5200–5214 nucleotide 
position (5′-GTTGAAAAAAAGTTA-3′); OCT1: 5116–5129 nucleotide position (5′-
CATCCTGAAAAATA-3′); 5143–5146 nucleotide position (5′-ACTCTTTTAATG-3′); NFκB: 
5188–5197 nucleotide position (5′-CGGGCCTCCC-3′); TATA-like sequences: 5146–5160 
nucleotide position (5′-CTTTTAATGTCCTCC-3′); 5202–5212 nucleotide position (5′-
TGAAAAAAAG-3′); 5256–5265 nucleotide position (5′-TGTTTATCAG-3′); E: experienced HIV-1-
positive patients; N: naive HIV-1-positive patients. 
Nucleotide substitutions are in bold red text. Deletions are indicated by bold and red dashes 
The area highlighted in light gray represents overlapping areas within one or more binding sites. 
The number of base pair (bp) of each sequence is reported on the right of the Figure. 
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The concomitant analysis of 23 NCCR regions amplified from the 23/66 (35%) MCPyV-positive 
rectal swabs (MCPyV 4,7,8,12,26,29,34,35,37,39,57,61,65,66 belonging to experienced (E) patients 
and MCPyV 13,14,21,23,36,38,43,55,64 belonging to naïve (N) patients) showed the presence of 
several mutations (Figure 4). Deletions were detected throughout the sequence between 
nucleotides 5094 and 5260 (Figure 4). The 5101 T to G and the 5102 G to T nucleotide transversions 
were detected in the strains MCPyV 4, 8, 14, 34, 39, and 61, whereas the 5098 C to G nucleotide 
transversion was found in MCPyV 35, 36, 38, 43, 55, and 57. The 5109 T to C nucleotide transition 
characterized the strains MCPyV 4, 8, 12, 21, 34, 39, and 61 (Figure 4). In MCPyV 13, 14, 23, 26, 29, 
35, 36, 37, 38, 39, 55, 57, and 66, the 5148 T to C transition was detected (Figure 4). The 5171, 5175, 
and 5176 A to T nucleotide transversions, the 5220 T to C transition, and the G to C transversion, 
located at position 5252 in MCPyV 34 and 55, were frequently detected in multiple MCPyV strains, 
as shown in Figure 4. Lastly, the GTT insertion at positions 5210–5211 in MCPyV 4, 7, 8, 29, 35, 38, 
39, and 61, and the GTTGA insertion at positions 5210–5211 in MCPyV 12, 13, 36, 37, 43, and 64 were 
also found (Figure 4).  
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Figure 4. Sequence analysis of the MCPyV NCCR recovered from rectal swabs. The alignment is 
shown between the nucleotide sequence from 5077 to 5280 of the published sequence of MCPyV in 
GenBank (NCBI) (EU375803) [2] and that obtained from the sequencing of rectal swabs positive for 
MCPyV NCCR (MCPyV 4,7,8,12,13,14,21,23,26,29,34,35,36,37,38,39,43,55,57,61,64,65,66). AP-1: 
5104–5114 nucleotide position (5′-GATGATGCCCC-3′); 5164–5172 nucleotide position (5′-
CTTTGTAAG-3′); 5257–5265 nucleotide position (5′-GTTTATCAG-3′); 5261–5269 nucleotide 
position (5′-ATCAGTCAA-3′); NF1: 5088–5105 nucleotide position (5′-
TATTGGCCAGCAGTGTG-3′); TST1: 5200–5214 nucleotide position (5′-
GTTGAAAAAAAGTTA-3′); OCT1: 5116–5129 nucleotide position (5′-CATCCTGAAAAATA-
3′); 5143–5146 nucleotide position (5′-ACTCTTTTAATG-3′); NFκB: 5188–5197 nucleotide 
position (5′-CGGGCCTCCC-3′); TATA-like sequences: 5146–5160 nucleotide position (5′-
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CTTTTAATGTCCTCC-3′); 5202–5212 nucleotide position (5′-TGAAAAAAAG-3′); 5256–5265 
nucleotide position (5′-TGTTTATCAG-3′); E: experienced HIV-1-positive patients; N: naive HIV-1-
positive patients. 
Nucleotide substitutions are in bold red text. Deletions are indicated by bold and red dashes. 
The area highlighted in light gray represents overlapping areas within one or more binding sites. 
The number of base pair (bp) of each sequence is reported on the right of the Figure. 
No significant association was found between the presence of GTT and GTTGA insertions and 
age and HIV patient’s status (naïve/experienced). It is interestingly to note that the presence of 
insertions was exclusively found in male gender with a statistical difference very close to 
significance (p = 0.054).  
The main NCCR modifications observed in MCPyV-positive patients, relative to analyzed 
samples, are summarized in Table 3. 
Table 3. Summary of the main NCCR modifications observed in MCPyV-positive patients relative 
to analyzed samples. 
Patients, 
n° 
N/E Age GENDER 
NCCR MODIFICATIONS 
URINE PLASMA RECTAL SWAB 
4 E 29 M   ∆GCA, ∆CC, insGTT 
7 E 36 M   ∆GCA, ∆CCC, insGTT  
8 E 46 M   ∆AA, insGTT  
11 E 55 M ∆CC, ∆AA  Not detected 
12 E 37 M   ∆CC, ∆TT, insGTTGA  




14 N 68 M   ∆GCA, ∆AA, ∆GA, insGTTGA  
19 N 42 M ∆CC  Not detected 
21 N 36 M  ∆CC, ∆AA ∆AA, ∆TTG 
23 N 50 M   ∆ATG, ∆CC, ∆AA 
26 E 41 F  ∆CC, ∆AA ∆TGA, ∆ATG, ∆CC, ∆AA 
27 E 38 M ∆CC, ∆AA   
29 E 38 M   ∆GA, ∆CC, ∆AA, ins GTT  
30 E 39 F ∆CCCCCC  Not detected 
34 E 30 M   ∆CC, ∆AA 
35 E 40 M  ∆CC ∆CC, insGTT  





∆GA, ∆ATG, 2∆AA, ∆TTTTGTTT, 
insGTTGA  
37 E 61 M   ∆GA, ∆CC, ∆AA, insGTTGA  
38 N 45 M ∆AA  ∆CCCC, 2∆AA, insGTT  
39 E 25 M   ∆GCA, ∆CCC, insGTT  




41 N 28 M  ∆AA Not detected 
42 E 28 M  Not detected Not detected 
43 N 46 M   insGTTGA  




55 N 45 M   ∆ATG, ∆CC 
57 E 34 M   ∆TGATGA, ∆CC, ∆AA 
61 E 43 M   ∆GCA, ∆CCAA, insGTT 
64 N 45 F 
Not 
detected 
 ∆GA, ∆CC, ∆CT, insGTTGA  
65 E 60 M 
Not 
detected 
 ∆GA, ∆ATG, ∆CC, ∆AAAAA, 
insGTTGA  
66 E 44 F   ∆GA, ATG, ∆CC, ∆AAAAA 
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n°: number of patients; N: naïve: E: experienced; ins: insertion; ∆: nucleotide deletion. 
3.3. Analysis of Putative Binding Sites in NCCR Sequences 
Analysis of putative binding sites was carried out on the NCCR sequence of the prototype 
MCC350 [2], ranging in nucleotide positions from 5077 to 5280, using TFBIND software, available 
at http://tfbind.hgc.jp/ [29]. Results showed the presence of putative binding sites for several 
transcription factors, including NF1, NFκB, Tst-1, OCT1, AP-1, and TATA (Figure 1). Specifically, 
the NF1 binding site (5′-TATTGGCCAGCAGTGTG-3′) was found into nucleotide positions 5088–
5105 whereas the single NFκB (5′-CGGGCCTCCC-3′) was identified into nucleotide positions 5188–
5197 (Figure 1). A Tst-1 element 5′-GTTGAAAAAAAGTTA-3′ was observed in 5200–5214 
nucleotide positions. Double sequences corresponding to OCT1 binding sites were detected at 
nucleotide positions 5116–5129 (5′-CATCCTGAAAAATA-3′) and 5143–5146 (5′-ACTCTTTTAATG-
3′). Moreover, multiple binding sites for AP-1 were present and placed in the following nucleotide 
positions: 5104–5114 (5′-GATGATGCCCC-3′), 5164–5172 (5′-CTTTGTAAG-3′), 5257–5265 (5′-
GTTTATCAG-3′), and 5261–5269 (5′-ATCAGTCAA-3′) (Figure 1). Additionally, three TATA-like 
sequences were inserted into nucleotide positions 5146–5160 (5′-CTTTTAATGTCCTCC-3′), 5202–
5212 (5′-TGAAAAAAAG-3′), and 5256–5265 (5′-TGTTTATCAG-3′) (Figure 1). Further DNA 
putative binding motifs, such as Sp1 and/or p53, already found in NCCR of other HPyVs [13,30] 
were not seen in reference NCCR MCC350 sequence. All sequences, recovered from MCPyV-
positive urine, plasma, and rectal swabs, isolated from the enrolled HIV-1-positive population, 
were compared to NCCR (5077–5280 bp) reference sequence MCC350 [2] for the examination of the 
cellular transcription binding sites as reported above. Results evidenced that in urine, the putative 
NF1 binding site (nucleotide positions 5088–5105) was maintained in all analyzed strains, as well 
as AP-1 in 5164–5172 nucleotide position, NFκB in 5188–5197 nucleotide position, Tst-1 in 5200–
5214 nucleotide position, and TATA in 5202–5212 nucleotide position (Figure 2). Between 
nucleotide positions 5104–5114, 5116–5129, and 5146–5160, the AP-1, OCT1, and TATA elements 
were altered in several samples, as shown in Figure 2. In plasma, all MCPyV strains displayed 
several alterations within the putative binding sites allocated between 5077 and 51160 nucleotide 
positions (Figure 3). As observed in urine, 5164–5172 AP-1 putative binding site was always 
retained in all sequences. NFκB in 5188–5197 nucleotide positions resulted incomplete in MCPyV 
26 and 35, whereas in MCPyV 42, it was characterized by a G to C transversion (Figure 3). Insertions 
and deletions altered the sequences of 5200–5214 Tst-1 and 5202–5212 TATA elements in all MCPyV 
samples with the exception of MCPyV 21 and 41 (Figure 3). Among nucleotide positions 5246–5280, 
MCPyV 36 conserved the deletions found in urine, altering the canonical configuration of AP-1 and 
TATA putative sites (Figure 3). Regarding sequences recovered from MCPyV-positive rectal swabs, 
although all strains showed an unchanged NFκB element, several alterations, including deletions 
or single base substitutions, were detected throughout the NCCR sequence (Figure 4). Interestingly, 
as previously described for plasma, the GTT and GTTGA insertions, into nucleotide positions 5210–
5211, changed the sequence of TSt-1 and TATA elements in MCPyV 4, 7, 8, 12, 13, 14, 29, 35, 36, 37, 
38, 39, 43, 64, and 65 (Figure 4). 
4. Discussion 
A direct link between immunosuppression and the development of opportunistic infections 
has been established, and it is also known that HPyVs, that commonly infects healthy humans, have 
a clearly established potential for causing severe organ damage or malignant transformation, 
especially in individuals with weakened immunity [31–34]. Although it is well defined that 
HIV/AIDS predisposes to viral infection and to development of MCC, up to now, very few studies 
focused on MCPyV prevalence and viral load in HIV-1-positive individuals without MCC [35]. 
Published data demonstrated that levels of anti-MCPyV IgG in HIV/AIDS patients were 
significantly higher than those in non-AIDS HIV-infected patients and the prevalence of MCPyV-
DNA in peripheral blood mononuclear cells (PBMCs) of HIV/AIDS and non-AIDS HIV-infected 
patients were 17% and 16%, respectively [36]. Moreover, Fukumoto and colleagues found that 9/23 
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(39%) serum samples from HIV patients, without highly active antiretroviral therapy (HAART) 
therapy, were MCPyV-positive [37]. Lastly, MCPyV DNA was found in 2/19 (11%) urine samples 
of HIV patients, as reported by Torres and colleagues [38]. 
In this framework, the aim of our study was to evaluate the prevalence and MCPyV loads in 
urine, plasma, and rectal swabs, among an HIV-1-positive population, in order to better understand 
MCPyV tissue tropism and to provide new insights on the possible pathogenic role of this virus in 
human diseases. Our results showed that MCPyV DNA was detected in all type of analyzed 
specimens, suggesting that the renal epithelium, blood, and gastrointestinal tract could be 
considered a target of the virus infection. The viral DNA detection confirms that MCPyV is 
widespread among the population, supporting the urine–oral and fecal–oral routes of transmission 
[39,40]. In our patients, higher MCPyV prevalence and a higher amount of MCPyV DNA were 
found in rectal swabs compared with urine and plasma samples. Since some authors reported 
evidence of HPyVs infection in anal/rectal samples from men who had sex with men, both in HIV-
1-positive and in negative population, with higher frequency of MCPyV infection, it is possible to 
suggest also the sexual route as a possible route of transmission of HPyVs in humans [5,40,41]. 
Moreover, as suggested by Vergori and colleagues, the higher MCPyV prevalence in rectal 
swabs could be related to differences in local mucosal immunity activity. In other sites of infection, 
viral reactivation could be less likely when compared with anal/rectal compartments, where 
traumatisms and the occurrence of sexually transmitted diseases may decrease the ability of the 
host to clear virus [5,42]. It is also plausible that the renal epithelium and blood may represent latent 
sites of the virus, rather than a site of active replication. This assumption is in agreement with 
HPyVs biology: it is well recognized that primary HPyVs infection is followed by the establishment 
of an asymptomatic latency state, possibly in the lymphoid, neuronal, kidney, hematopoietic tissues, 
characterized by low-level replication and excretion, for example, in urine [10,43]. Although no 
significant association was found between the presence of MCPyV DNA and HIV patient’s status 
at enrollment, MCPyV DNA was found in a higher percentage in naïve patients compared with 
experienced ones, either in single or all anatomical sites. This data suggest that a weakened immune 
system with low CD4+ counts as often reported in naïve patients might favor MCPyV replication. 
In order to improve the knowledge of NCCR alterations in MCPyV strains circulating in the context 
of immunosuppression, the NCCR variability was analyzed. NCCR rearrangements are described 
as a pivotal event in the onset of HPyVs-related pathology, as demonstrated for JCPyV and BKPyV 
in which NCCRs not only control gene expression but also serve as main determinants in viral 
replication, containing the origin of DNA replication and transcription factor binding sites [15,44]. 
Instead, little is known regarding the role of NCCR in MCPyV infection, and limited data are 
available about the relationship between MCPyV NCCR strains and MCPyV pathogenesis. NCCR 
sequence analysis revealed a high degree of homology with MCC350 strain in urine, whereas 
transitions, transversions, and single or double deletions were observed in plasma and rectal swabs. 
Differently to JCPyV and BKPyV, in which the early proximal side of NCCR is highly conserved 
and the late proximal side undergoes rearrangements [15], we found that insertions and deletions 
occurred both in early and in late proximal side of the MCPyV NCCR. Specifically, in the analyzed 
strains, representative GTTGA and GTT insertions (nucleotide positions 5210–5211) were observed 
in both plasma and rectal swabs. Interestingly, these alterations were found exclusively in male 
gender with a statistical difference very close to significance (p = 0.054). The MCPyV NCCR 
structure, in contrast to JCPyV and BKPyV, has been previously associated with the geographic 
origin of the patients [13]. Hashida and colleagues identified two major subtypes of MCPyV NCCR, 
subtypes I and II, with the presence or absence of a 25 bp tandem repeat 
(TGTCCTCCTCCCTTTGTAAGAGAAA) into nucleotide positions 5177–5178, respectively. Based 
on the occurrences of two additional insertions (2 bp, TT, and 5 bp insertions, GTTGA, between 
nucleotide positions 5199–5200 and 5210–5211, respectively), MCPyV strains were assigned further 
to five genotypes. In our analyzed strains, we found the MCPyV NCCR IIa-2 strain in plasma and 
rectal swabs, which contain the 5 bp insertion and represents the predominant strain among white 
persons of European descent, as predictable for our cohort of patients [13]. In this study, we 
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evaluated beside the NCCR rearrangements the possible nucleotide changes that fell within the 
putative binding sites for cellular transcription factors [13,30,44,45]. Sequence analysis showed that 
MCC350 NCCR sequence contains the NF1, NFκB, Tst-1, OCT1, AP-1, and TATA binding sites 
already described within the NCCRs of other HPyVs [13,30,44,45]. In several strains obtained from 
MCPyV-positive samples, deletions, insertions, or single base substitutions fell within these 
putative binding sites. It can be envisaged that some of these changes did not allow the 
identification of putative binding motifs such as Sp1 and/or p53, already described in the NCCR of 
other HPyVs [13], in our NCCR sequences. The relevance of cellular factors such as Tst-1, NF-1, 
Sp1, NF-kB, and PURα, that specifically determine JCPyV tropism for glial cells and play an 
important role in efficient HPyVs DNA replication, is well described [46]. Moreover, a potential 
association, between a C/G mutation in the NCCR Sp1 site and increased BKPyV virulence in 
hemorrhagic cystitis (HC) patients, has been proposed [47]. In light of these findings, further 
studies are warranted in order to define the importance of these NCCR binding sites and 
understand how their changes (mutations, insertions, or deletions) may drive MCPyV replication 
and subsequent in vivo pathogenicity. Finally, in the attempt to understand whether 
rearrangements could be correlated to a higher replicative capacity, the median MCPyV viral load 
of each district was analyzed in relation to the presence of rr-NCCRs, confirming that the MCPyV 
strains that carried the GTTGA insertion in NCCR showed a higher rate of replication compared 
with the ones without insertion, either in the same or different anatomical sites. As previously 
reported for BKPyV and JCPyV, rr-NCCRs conferred a higher replication rate to these viruses 
contributing to diseases progression [22]. Consequently, also for MCPyV, it is possible to speculate 
that the shift from canonical NCCR to rr-NCCR could determine higher replication capacity and 
increase the pathogenic potential in the context of immunosuppression. It is also likely that high 
MCPyV-DNA levels might increase the chance of its integration into the host cell genome and, then, 
its oncogenic properties in a context different from that of MCC. 
5. Conclusions 
Based on the high prevalence of MCPyV in rectal swabs, we suggest that sexual route can 
represent another route of transmission of HPyVs among humans. Although sequencing analysis 
revealed the presence of numerous mutations in the NCCR, whether these mutations may have an 
impact on the pathogenic features of the virus remains to be determined. The study adds important 
information about MCPyV prevalence, viral load, and NCCR behavior in HIV-positive individuals 
and suggests to monitor the possible role of MCPyV in triggering disease outside the MCC context. 
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